Thermal glucoside byproduct bacillus with efficient degradation capacity and application
By screening and identifying Bacillus T5, a byproduct of thermoglucosinolate production, the problem of simultaneously and efficiently degrading AFB1 and ZEA by biological methods under high temperature conditions has been solved, achieving a highly efficient and stable detoxification effect, which is applicable to the field of food safety.
Patent Information
- Application Number
- CN202511363579.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-09-23
- Publication Date
- 2026-01-09
AI Technical Summary
Existing biological methods for degrading aflatoxin B1 (AFB1) and zearalenone (ZEA) suffer from problems such as low strain degradation efficiency, poor thermal stability, and difficulty in simultaneously and efficiently degrading both toxins, especially limiting their application in high-temperature environments.
A strain of thermoglucosidasius T5, a byproduct of thermoglucosinolate production, was screened and identified. This strain can efficiently degrade AFB1 and ZEA at high temperatures and has excellent thermal stability. The active ingredients in the fermentation broth can be used for detoxification of feed and grain.
It achieved efficient degradation of AFB1 and ZEA. The supernatant of the fermentation broth showed a degradation rate of 91.81% for 500 μg/L AFB1 and 89.97% for ZEA. It also maintained a high degradation rate after heat treatment at 100℃, making it suitable for food safety applications in high-temperature environments.
Smart Images

Figure CN121294232A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of microbial technology, specifically to a thermoglucosinolate by-product spore-forming bacillus with highly efficient degradation capabilities. Background Technology
[0002] Aflatoxin B1 (AFB1) is one of the most potent toxins known to humans and animals, exhibiting teratogenic, immunotoxic, genotoxic, mutagenic, and carcinogenic effects. Zearalenone (ZEA) is the most prevalent mycotoxin in grains and food worldwide, primarily affecting the animal reproductive system, increasing estrogen levels, and causing damage to the immune system, digestive system, and liver. AFB1 and ZEA often co-exist in grains, and their widespread contamination and high toxicity pose a serious threat to food safety and animal husbandry. Effective removal of these two secondary metabolites has long been a goal.
[0003] Currently, methods for removing mycotoxins mainly include physical, chemical, and biological methods. While physical methods (such as adsorption and heating) and chemical methods (such as degradation using chemical reagents) can remove toxins to some extent, they have drawbacks such as damaging the nutritional value of food, introducing chemical residues, and having limited applicability, resulting in low application rates in the food industry. Biological detoxification, with its advantages of high efficiency, environmental friendliness, and safety, can minimize the loss of nutritional value and characteristics of food, making it the preferred approach for addressing AFB1 and ZEA contamination. However, existing biological detoxification technologies have significant bottlenecks: single-enzyme systems have limited multi-target degradation capabilities, making it difficult to simultaneously and efficiently degrade AFB1 and ZEA; the toxicity risks of metabolic intermediates remain unclear; and insufficient thermal stability of enzyme molecules limits industrial application (especially in scenarios requiring high-temperature processing, such as feed processing). Therefore, screening for a strain capable of simultaneously and efficiently degrading AFB1 and ZEA with good thermal stability is of great significance for solving the problem of mycotoxin contamination in actual production. Summary of the Invention
[0004] The purpose of this invention is to overcome the shortcomings of existing technologies in the biological degradation of AFB1 and ZEA, such as low degradation efficiency, poor thermal stability, and difficulty in simultaneously degrading the two toxins. This invention provides a strain of parageobacillus thermoglucosidasius T5, which can simultaneously and efficiently degrade AFB1 and ZEA, and has excellent thermal stability. The active ingredients in its fermentation broth can be directly used for detoxification of feed and grains, and have broad prospects for industrial application.
[0005] To solve the above-mentioned technical problems, the technical solution provided by the present invention is as follows:
[0006] A highly efficient thermoglucosidase byproduct of spore production, classified as Parageobacillus thermoglucosidasius T5, is deposited at the China Center for Type Culture Collection (CCTCCNO:M20251790). Its 16S rDNA sequence is shown in SEQ ID NO.1.
[0007] Preferably, the primers used to identify thermoglucosinolate-producing Bacillus include forward primer 27F and reverse primer 1492R;
[0008] The nucleotide sequence of the forward primer 27F is shown in SEQ ID NO.2;
[0009] The nucleotide sequence of the reverse primer 1492R is shown in SEQ ID NO.3.
[0010] Preferably, SEQ ID NO.2 is 5'-TACGGCTACCTTGTTACGACTT-3', and SEQ ID NO.3 is 5'-TACGGCTACCTTGTTACGACTT-3'.
[0011] This invention also relates to a method for identifying a thermoglucosinolate by-product spore-forming bacterium with highly efficient degradation capabilities, comprising the following steps:
[0012] a. Extract genomic DNA from the strain to be identified;
[0013] b. Using the genomic DNA extracted in step a as a template, PCR amplification was performed using the forward primer 27F and the reverse primer 1492R; the PCR amplification reaction system consisted of: 2.5 μL of DNA template, 1 μL of 1×10⁻⁶ m³ / h⁻¹ ... -5 mol / L forward primer, 1 μL of 1×10 -5 The reagents included mol / L reverse primers, 25 μL of 2×Taq PCR StarMix, and 20.5 μL of ddH2O. The PCR amplification conditions were as follows: pre-denaturation at 94℃ for 10 min; followed by denaturation at 94℃ for 30 s, annealing at 52℃ for 30 s, extension at 72℃ for 90 s, for 30 cycles; and a final extension at 72℃ for 5 min.
[0014] c. Sequencing the PCR amplification products and comparing the sequenced sequence with the sequence shown in SEQ ID NO.1. If the homology is ≥99%, the strain to be identified is Bacillus thermoglucosinolate-producing.
[0015] This invention also relates to the application of a thermoglucosinolate by-product Bacillus with highly efficient degradation capabilities in the degradation of aflatoxin and gibbenone.
[0016] Preferably, the application includes the following steps: contacting the fermentation broth of *Bacillus thermoglucosinolates* or its supernatant with a sample containing AFB1 and / or ZEA at 55-65°C for 72 hours; the fermentation supernatant is prepared by the following method: centrifuging the fermentation broth of *Bacillus thermoglucosinolates* at 4°C and 8000 r / min for 6 minutes, collecting the supernatant, filtering it through a 0.22 μm sterile filter membrane, and collecting the supernatant to obtain the antidote.
[0017] Preferably, the sample containing AFB1 and / or ZEA is feed or grain; the volume-to-mass ratio of the fermentation broth supernatant to the sample is (1-5):10.
[0018] Preferably, the active ingredient in the antidote is a protein or enzyme, and after heat treatment at 100°C for 15 minutes, the degradation rate of AFB1 is still ≥60% and the degradation rate of ZEA is still ≥55%.
[0019] Preferably, the antidote, when used at 55-65°C, exhibits a degradation rate of ≥90% for AFB1 at a concentration of 500 μg / L and a degradation rate of ≥85% for ZEA at a concentration of 500 μg / L.
[0020] By employing the above method, the present invention has the following advantages:
[0021] 1. Highly Efficient Degradation Capacity for Two Toxins: Strain T5 can simultaneously and efficiently degrade aflatoxin B1 (AFB1) and juvenile toxin ester (ZEA), with outstanding degradation efficiency. Experimental data show that its fermentation broth supernatant achieved a degradation rate of 91.81% for AFB1 at a concentration of 500 μg / L and 89.97% for ZEA at the same concentration. This overcomes the bottleneck of "limited degradation capacity of single enzyme / single strain at multiple targets" in traditional biological detoxification methods and can effectively address the practical problem of co-contamination of two toxins in grains.
[0022] 2. Excellent thermal stability: On the one hand, the optimal growth temperature of the strain is 60℃, and it can proliferate normally in high-temperature environments, making it suitable for high-temperature composting, feed processing and other scenarios that require tolerance to certain temperatures; on the other hand, its key active components for degrading toxins (extracellular proteins / enzymes) have good heat resistance. After a 15-minute boiling water bath at 100℃, the degradation rates of AFB1 and ZEA still remain at 60.2% and 56.7%, respectively, avoiding the limitations of industrial application caused by the insufficient thermal stability of conventional enzyme molecules.
[0023] 3. Clear identification of active ingredients: Through group experiments (comparison of fermentation broth supernatant, bacterial suspension, intracellular fluid, etc.), it was clarified that the core functional components of toxin degradation are the active substances secreted extracellularly during fermentation, rather than the components adsorbed by the bacteria themselves or intracellular components. This provides a clear direction for the subsequent separation, purification and large-scale preparation of active ingredients, and reduces the technical difficulty of application development.
[0024] The above overview is for illustrative purposes only and is not intended to be limiting in any way. In addition to the illustrative aspects, embodiments, and features described above, further aspects, embodiments, and features of the invention will become readily apparent from the accompanying drawings and the following detailed description. Attached Figure Description
[0025] To more clearly illustrate the technical solutions in the embodiments of this application or the prior art, the drawings used in the description of the embodiments or the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of this application. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.
[0026] Figure 1 This is a schematic diagram of T5 colonies in this invention;
[0027] Figure 2 This is a schematic diagram of the Gram-positive bacteria of the present invention;
[0028] Figure 3 This is an electrophoresis diagram of the PCR products of the strain of this invention;
[0029] Figure 4 This is the T5 phylogenetic tree diagram of the present invention;
[0030] Figure 5 This is a growth curve of the strain of the present invention;
[0031] Figure 6 This is the mass spectrum peak diagram of the strain of this invention;
[0032] Figure 7 This is a schematic diagram illustrating the degradation of toxins by different components of the present invention;
[0033] Figure 8 This is a schematic diagram illustrating the effects of different treatments of the present invention on toxin degradation. Detailed Implementation
[0034] Specific embodiments of the invention will now be described in detail. Although the invention is described in conjunction with these specific embodiments, it should be understood that the invention is not intended to be limited to these specific embodiments. Rather, these embodiments are intended to cover alternative, modified, or equivalent embodiments that may be included within the spirit and scope of the invention as defined by the claims. In the following description, numerous specific details are set forth in order to provide a thorough understanding of the invention. The invention may be practiced without some or all of these specific details. In other instances, well-known processes have not been described in detail so as not to unnecessarily obscure the invention.
[0035] When used in conjunction with the terms "comprising," "method comprising," or similar language in this specification and appended claims, the singular forms "a," "some," and "the" include plural references unless the context clearly indicates otherwise. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains.
[0036] The present invention will now be described in further detail with reference to the full text.
[0037] Combined with appendix Figures 1-8 The purpose of this invention is to overcome the shortcomings of existing technologies in the biological degradation of AFB1 and ZEA, such as low degradation efficiency, poor thermal stability, and difficulty in simultaneously degrading the two toxins. This invention provides a strain of thermoglucosidase byproduct Bacillus T5 (classification name: Parageobacillus thermoglucosidasius T5, deposited on August 7, 2025 at the China Center for Type Culture Collection, Wuhan University, China, accession number CCTCCNO: M20251790). This strain can simultaneously and efficiently degrade AFB1 and ZEA, and has excellent thermal stability. The active ingredients in its fermentation broth can be directly used for detoxification of feed and grains, showing broad prospects for industrial application.
[0038] Another objective of this invention is to provide specific primer pairs and identification methods for identifying the strain, thereby ensuring the accurate identification and application of the strain.
[0039] Another objective of this invention is to provide a method for culturing the strain and its application in the degradation of AFB1 and ZEA, as well as an antidote based on the fermentation broth of the strain, providing a practical solution for toxin control in the field of food safety.
[0040] To achieve the above objectives, the present invention adopts the following technical solution:
[0041] A strain of thermoglucosinolate-producing Bacillus T5
[0042] This invention isolated and screened a strain with highly efficient AFB1 and ZEA degradation capabilities from high-temperature composting. Based on morphological observation, Gram staining, and 16S rDNA sequence analysis, it was identified as a thermoglucosinolate byproduct of Bacillus thermoglucosidasius and named T5. The 16S rDNA sequence of this strain, as shown in SEQ ID NO.1, has been compared with the NCBI database using BLAST and shows the closest evolutionary lineage to Parageobacillus thermoglucosidasius, with ≥99% homology.
[0043] This strain has the following biological characteristics:
[0044] Morphological characteristics: Colonies are round, with clear borders, opaque, pale yellow, smooth, moist, and easy to pick up; Gram-positive, with the cell wall showing a characteristic purple staining.
[0045] Growth characteristics: The optimal growth temperature is 60℃. In LB liquid medium (initial pH 7.5-7.6), under the conditions of 60℃ and 180r / min, the exponential growth phase is 0-24h, the stationary phase is 48h, and the decline phase is 72-96h. During the culture process, the pH of the medium gradually increases and is maintained at an alkaline homeostasis of 8.80-8.92. The peak of extracellular protein secretion occurs at 48h, with the highest concentration reaching 0.26mg / mL.
[0046] Toxin degradation characteristics: At 60℃, the supernatant of the fermentation broth of this strain can achieve a degradation rate of 91.81% for 500 μg / L AFB1 and 89.97% for 500 μg / L ZEA. The degradation activity mainly comes from protein or enzyme substances in the fermentation broth, and the active ingredient has good thermal stability. After heat treatment at 100℃ for 15 min, the degradation rate of AFB1 still remains ≥60% and the degradation rate of ZEA still remains ≥55%, which can be adapted to high-temperature processing scenarios such as feed processing.
[0047] Primer pairs and identification methods used to identify strain T5:
[0048] For the 16S rDNA sequence of strain T5, this invention designed and screened specific primer pairs, including forward primer 27F (SEQ ID NO.2) and reverse primer 1492R (SEQ ID NO.3). These primer pairs can specifically amplify the 16S rDNA fragment of strain T5, with an amplification product length of approximately 1.5 kb, enabling accurate identification of the strain through sequencing alignment.
[0049] The method for identifying strain T5 using this primer pair includes three steps: genomic DNA extraction, PCR amplification, and sequencing alignment. The PCR reaction system and reaction conditions have been optimized to ensure amplification efficiency and specificity.
[0050] Culture method of strain T5:
[0051] To achieve efficient cultivation of strain T5 and the abundant secretion of active ingredients, this invention optimizes the cultivation conditions, including the selection of culture medium, temperature, rotation speed, and pH control. Specifically, LB liquid medium is used, and the strain is cultivated at 60℃ and 180 r / min. By controlling the inoculum size and the number of subcultures, a high-biomass bacterial solution and a fermentation broth rich in active degradation components can be obtained within 24-48 hours, meeting the needs of industrial production.
[0052] Applications and antidotes of strain T5:
[0053] The strain T5 described in this invention can be directly used to degrade AFB1 and / or ZEA, and is particularly suitable for the control of toxin contamination in samples such as feed and grains. In application, the fermentation broth or supernatant of strain T5 can be contacted with the toxin-containing sample at 55-65℃ for 72 hours to achieve efficient detoxification. The fermentation supernatant is prepared by centrifugation and filtration, which removes bacterial cells, making it more convenient to use and avoiding any potential impact of bacterial cells on the sample.
[0054] The detoxifying agent based on the supernatant of fermentation broth of strain T5 has active ingredients that are proteins or enzymes with toxin degradation activity. The preparation process is simple and convenient to use. It has high degradation efficiency for AFB1 and ZEA at 55-65℃ and excellent thermal stability. It can be widely used in grain storage, feed processing and other fields to effectively reduce the risk of toxin contamination.
[0055] Example 1: Isolation of strain T5.
[0056] Bacterial resuscitation: Under aseptic conditions, pick a single colony and inoculate it into 10 mL of LB liquid medium. Incubate at 60°C and 180 rpm for 24 h on a shaker. Streaking: Use a sterile inoculating loop to inoculate an appropriate amount of bacterial suspension onto solid LB medium. After marking, incubate at 60°C to allow single colonies to grow for subsequent experiments.
[0057] Gram staining: Under aseptic conditions, use an inoculation loop to pick a single colony and place it on a glass slide, then add sterile physiological saline to dilute and mix. Heat with the outer flame of an alcohol lamp until the strain is completely fixed on the glass slide, add crystal violet staining solution and stain for 1 min, then rinse with distilled water to remove any remaining dye; add Gram's iodine solution and stain for 1 min, then rinse again with distilled water; add 95% ethanol to decolorize for 30 s and rinse; add safranin staining solution to counterstain for 1 min, rinse and air dry, then add pine oil and observe the colony morphology under a microscope.
[0058] Subculturing: Working in a clean bench, single colonies were collected from solid LB medium using an inoculation loop and inoculated into 10 mL of LB liquid medium. The culture was then placed in a constant temperature shaker at 60°C and 180 rpm for 24 h. The cultured bacterial suspension was then subcultured at a 1% inoculum for subsequent experiments.
[0059] Results of strain identification, morphological observation, and staining:
[0060] from Figure 1-2 It can be seen that T5 colonies are round, with clear borders, opaque, pale yellow, smooth, and moist, making them easy to pick up; Gram staining results show that their cell walls exhibit characteristic purple staining, which meets the classification criteria for Gram-positive bacteria.
[0061] Example 2: 16S rDNA identification:
[0062] a. DNA extraction: Single colonies were picked and inoculated into LB liquid medium and incubated overnight at 60°C and 180 rpm. Genomic DNA was extracted using a bacterial genome extraction kit.
[0063] b. PCR amplification: PCR amplification was performed using primer pairs 27F (SEQ ID NO.2) and 1492R (SEQ ID NO.3). The PCR reaction system and conditions are shown in Table 1 and Table 2.
[0064] Table 1 PCR reaction system
[0065] Components volume DNA template 2.5μL <![CDATA[1×10 -5 mol / L forward primer 1μL <![CDATA[1×10 -5 mol / L reverse primer 1μL 2×TaqPCRStarMix 25μL <![CDATA[ddH2O]]> 20.5μL
[0066] Table 2 PCR reaction conditions
[0067]
[0068] c. Sequencing and Comparison: DNA from five strains was extracted using a kit and then amplified by PCR, such as... Figure 3 As shown, after the purity and quality of the PCR products were detected by agarose gel electrophoresis, the PCR products were sent to a sequencing company for sequencing. The assembled sequence (SEQ ID NO.1) was BLAST-aligned on the NCBI website. The sequences with high homology obtained from the alignment analysis were further used to construct a phylogenetic tree using MEGA11 software, as shown below. Figure 4 As shown.
[0069] The PCR amplification results of the strain are shown in the figure. A bright and single specific band appeared at 1.5 kb, and the amplification product was directly used for subsequent sequencing analysis. Based on BLAST sequence alignment from the NCBI database, phylogenetic analysis was performed on T5. The T5 strain is most closely related to the evolutionary branch of Parageobacillus thermoglucosidasius. Therefore, the final identification result is: T5 is Parageobacillus thermoglucosidasius.
[0070] Parageobacillus thermoglucosidasius.
[0071] Example 3:
[0072] Determination of the physicochemical properties of the bacterial strain, and preparation of the protein standard curve:
[0073] Take 5 mL of protein standard solution and dilute to 50 mL to make the concentration of the standard protein solution 100 μg / mL. Plot the standard curve according to Table 3.
[0074] Table 3. Preparation of Standard Protein Concentrations
[0075] 1 2 3 4 5 6 7 Standard protein solution (mL) 0 0.1 0.2 0.3 0.4 0.5 0.6 Distilled water (mL) 1.0 0.9 0.8 0.7 0.6 0.5 0.4 Protein concentration (μg / mL) 0 10 20 30 40 50 60
[0076] Pipette 100 μL of the solution from each tube into a 1.5 mL stoppered test tube, then add 500 μL of Coomassie Brilliant Blue solution, mix well, let stand for 2 min, measure A595, and plot a standard curve of absorbance versus protein concentration, ensuring that R² is above 0.999.
[0077] Determination of free protein content:
[0078] The content of free protein in the fermentation broth was determined by the Coomassie brilliant blue method: 2 mL of fermentation broth was taken, centrifuged at 8000 r / min for 6 min at 4℃, 1 mL of supernatant was taken and 5 mL of Coomassie brilliant blue solution was added, shaken well, and allowed to stand for 2 min. The absorbance at 595 nm was then measured.
[0079] Biomass determination:
[0080] Take 0.5 mL of bacterial culture from the middle of the Erlenmeyer flask and measure its absorbance at 600 nm (OD600). Use sterile culture medium as a blank to characterize the biomass.
[0081] Determination of growth curves:
[0082] The purified T5 single colonies were picked and placed into 10 mL of LB liquid medium, and incubated at 60 °C and 180 rpm for 24 h. Then, they were inoculated into 100 mL of LB medium at a 1% inoculum size and incubated at 60 °C and 180 rpm for 144 h. Samples were taken at the same time every day, the pH of the bacterial culture was measured using a pH meter, the protein content was determined using the Coomassie Brilliant Blue method, and the bacterial concentration was detected at OD600. Growth curves were plotted.
[0083] Growth curve of the strain:
[0084] Time-series growth curves ( Figure 5 The study revealed the typical growth kinetics of strain T5: exponential proliferation from 0 to 24 hours, a steady-state phase from 48 hours, and a decline phase from 72 to 96 hours. The initial culture medium pH of 7.52 significantly increased to 8.85 after 24 hours of culture, and maintained alkaline homeostasis (pH 8.80–8.92) during subsequent culture cycles. Extracellular protein secretion dynamics showed that the concentration continuously increased from 24 to 48 hours of culture, began to decline after 72 hours, and a second secretion peak appeared at 96 hours, with the peak concentration occurring at the 48-hour culture point, reaching a maximum concentration of 0.26 mg / mL.
[0085] Degradation effects of the strain on AFB1 and ZEA:
[0086] (1) Aflatoxin B1 and zearalenone were quantitatively analyzed by LC-MS. The chromatographic conditions were as follows: Waters BEHC18 (2.1 mm × 50 mm, 1.7 μm) column; column temperature: 40 ℃; mobile phase A: 4.0 mmol / L ammonium acetate-0.1% formic acid aqueous solution (pH 3.0); mobile phase B: methanol; flow rate: 0.3 mL / min; injection volume: 1.0 μL. The gradient elution conditions are shown in Table 4.
[0087] The mass spectrometry conditions were as follows: ESI ion source; detection mode: multiple reaction monitoring (MRM), positive ion mode detection; spray voltage: 3500V (ESI+); ion source temperature: 350℃; curtain gas: 35psi; nebulizing gas (Gas1): 50psi; auxiliary heating gas (Gas2): 50psi; collision gas (CAD): medium; other parameters are shown in Table 5 below.
[0088] Table 4 Gradient Elution of Mobile Phase
[0089] Time / min A / % B / % 0.01 90 10 0.50 90 10 1.50 15 85 3.05 15 85 3.50 90 10 5.00 90 10
[0090] Table 5 Mass spectrometry parameters of AFB1 and ZEA
[0091]
[0092] (2) The previously prepared AFB1 and ZEA stock solutions were diluted with chromatographic grade methanol to obtain AFB1 and ZEA solutions with concentrations of 5 μg / L, 15 μg / L, 25 μg / L, 50 μg / L, 75 μg / L, 100 μg / L, 150 μg / L, and 200 μg / L, respectively. After filtration through a 0.22 μm filter membrane, the solutions were transferred to brown sample vials. High performance liquid chromatography-mass spectrometry was used for detection, and standard curves were plotted.
[0093] (3) After the strain was activated, single colonies were picked and inoculated into 10 mL of LB medium (containing a final concentration of 500 μg / LAFB1 and ZEA). Uninoculated LB medium containing 500 μg / LAFB1 and ZEA was used as a blank control. The culture was carried out at 60℃ and 180 r / min for 72 h in a constant temperature shaker. 1 mL of the culture was taken and centrifuged at 8000 r / min for 6 min. The supernatant was extracted with 3 times the volume of dichloromethane, vortexed for 60 s, and the lower organic phase was collected. The organic phase was dried with nitrogen evaporator, dissolved in 1 mL of methanol, sonicated for 30 min, passed through a 0.22 μm organic membrane, and placed in a sample vial to detect the contents of AFB1 and ZEA.
[0094] Toxin degradation rate = (1 - residual toxin / initial toxin content) x 100%.
[0095] Localization of active components in strains that degrade toxins
[0096] T5 was inoculated into LB medium (100 mL) at a 1% inoculum and incubated at 60℃ and 180 rpm for 24 h. The toxin-degrading activity of the strain was localized, with three replicates from each group. The grouping treatments are as follows:
[0097] Group A (fermentation broth supernatant): Take 5 mL of the bacterial fermentation broth, centrifuge at 4℃ and 8000 r / min for 6 min, collect the supernatant and filter it through a sterile 0.22 μm filter membrane into a sterile centrifuge tube for later use.
[0098] Group B (bacterial suspension): After centrifugation in the previous step, the precipitate is gently rinsed 3-5 times with 5 mL of PBS buffer, then resuspended in 5 mL of PBS buffer and stored in a sterile centrifuge tube for later use.
[0099] Group C (intracellular fluid): Take 5 mL of the strain's fermentation broth and centrifuge at 4℃ and 8000 r / min for 6 min. Take the precipitate and gently wash it 3-5 times with 5 mL of PBS buffer. Then resuspend it with 5 mL of PBS buffer. Then sonicate it at 300W for 2 seconds, pause for 3 seconds, and in an ice bath for 30 min. Centrifuge at 8000 r / min for 10 min. After filtration through a sterile 0.22 μm filter membrane, transfer it to a new sterile centrifuge tube.
[0100] Group D (cell disruption and precipitation): Collect the precipitate from the previous step, add 5 mL of PBS to a sterile centrifuge tube and store for later use.
[0101] Group E (inactivated cells): Inactivated cell preparation: Centrifuge 5 mL of fermentation broth at 4℃ and 8000 r / min for 6 min, collect the precipitate, wash 3-5 times with PBS buffer, resuspend the cells in 5 mL of PBS buffer, and incubate at 100℃ for 15 min.
[0102] Take 3 mL from each of the five groups above, add AFB1 and ZEA to each group to a final concentration of 500 μg / L, and co-culture them in a 60℃ constant temperature shaker at 180 r / min for 72 h. Use LB medium containing AFB1 and ZEA to a final concentration of 500 μg / L as a blank control, and detect the degradation rate of AFB1 and ZEA by each component.
[0103] Sensitivity of active ingredients to proteinase K and heat treatment:
[0104] Group A (Control): Untreated fermentation fraction liquid;
[0105] Group B (Heat Treatment): 100℃ boiling water bath for 15 minutes;
[0106] Group C (proteinase K treatment): 1 mg / mL proteinase K was treated with fermentation component broth at 55℃ for 2 h;
[0107] Group D (proteinase K + SDS treatment): Proteinase K (1 mg / mL) + 1% SDS and fermentation component solution were treated at 55℃ for 2 h.
[0108] 3 mL of each of the four groups A, B, C, and D was added to each group, with a final concentration of 500 μg / L for AFB1 and ZEA. The mixtures were fermented at 60℃ and 180 r / min for 72 h, and the degradation rates of AFB1 and ZEA were then measured.
[0109] like Figure 6 As shown in the LC-MS peak file, T5 has a significant degradation effect on both AFB1 (charge-to-mass ratio 313) and ZEA (charge-to-mass ratio 319).
[0110] like Figure 7As shown in the figure, the degradation effects of different fractions of the fermentation broth of the five strains on AFB1 and ZEA were as follows: the fermentation supernatant (group A) showed the best degradation effects on AFB1 and ZEA, at 91.81% and 89.97%, respectively, which were significantly higher than those of bacterial suspension (group B, 26.32% and 18.62%), intracellular lysate (group C, 27.58% and 24.37%), cell lysate (group D, 18.55% and 16.38%), and heat-inactivated cells (group E, 15.32% and 14.52%). This result indicates that the extracellular secreted active enzymes during T5 fermentation are a common functional component in the degradation of both toxins.
[0111] like Figure 8 As shown, the degradation rate of AFB1 in the T5 supernatant treated with proteinase K decreased from 91.81% to 25.37%, and the degradation rate of ZEA decreased from 89.97% to 18.5%. Under the combined action of proteinase K and SDS, the degradation rate of AFB1 decreased to 18.78%, and the degradation rate of ZEA decreased to 13.2%. Experimental data indicate that proteins or enzymes in the supernatant are the main effectors of AFB1 and ZEA degradation. Heat treatment, by causing irreversible inactivation of temperature-sensitive components in the extracellular fluid, verified the key role of heat-sensitive biomolecules in metabolic processes. As shown in the figure, the degradation rate of AFB1 after heat treatment was 60.2%, and the degradation rate of ZEA was 56.7%, indicating that the key active components in the supernatant have good heat resistance properties.
[0112] >T516 Sribosomal RNA sequence (SEQ ID NO. 1).
[0113]
[0114] The present invention and its embodiments have been described above. This description is not restrictive, and the embodiments shown throughout are only one of the embodiments of the present invention. The actual structure is not limited to this. In conclusion, if those skilled in the art are inspired by this description and design similar structures and embodiments without departing from the spirit of the present invention, they should all fall within the protection scope of the present invention.
Claims
1. A thermoglucosinolate byproduct Bacillus strain with highly efficient degradation capabilities, characterized in that, Classification name: Parageobacillus thermoglucosidasius T5, deposited at China Center for Type Culture Collection, accession number CCTCCNO:M20251790, its 16S rDNA sequence is shown in SEQ ID NO.
1.
2. The thermoglucosinolate byproduct Bacillus strain with highly efficient degradation ability according to claim 1, characterized in that: Primers used to identify thermoglucosinolate-producing Bacillus include forward primer 27F and reverse primer 1492R; The nucleotide sequence of the forward primer 27F is shown in SEQ ID NO.2; The nucleotide sequence of the reverse primer 1492R is shown in SEQ ID NO.
3.
3. The thermoglucosinolate by-product Bacillus with highly efficient degradation ability according to claim 2, characterized in that: The SEQ ID NO.2 is 5'-TACGGCTACCTTGTTACGACTT-3', and the SEQ ID NO.3 is 5'-TACGGCTACCTTGTTACGACTT-3'.
4. The method for identifying a thermoglucosinolate by-product spore-forming bacterium with highly efficient degradation ability according to any one of claims 2-3, characterized in that: Includes the following steps: a. Extract genomic DNA from the strain to be identified; b. Using the genomic DNA extracted in step a as a template, perform PCR amplification using the forward primer 27F and the reverse primer 1492R; The PCR amplification reaction system includes: 2.5 μL of DNA template, 1 μL of 1×10⁻⁶ ppm... -5 mol / L forward primer, 1 μL of 1×10 -5 The reagents included mol / L reverse primers, 25 μL of 2×Taq PCR StarMix, and 20.5 μL of ddH2O. The PCR amplification conditions were as follows: pre-denaturation at 94℃ for 10 min; followed by denaturation at 94℃ for 30 s, annealing at 52℃ for 30 s, extension at 72℃ for 90 s, for 30 cycles; and a final extension at 72℃ for 5 min. c. Sequencing the PCR amplification products and comparing the sequenced sequence with the sequence shown in SEQ ID NO.
1. If the homology is ≥99%, the strain to be identified is Bacillus thermoglucosinolate-producing.
5. The application of a thermoglucosinolate-producing Bacillus strain with highly efficient degradation capabilities as described in any one of claims 1-3 in the degradation of aflatoxin and gibbenone.
6. The application according to claim 5, characterized in that: The application includes the following steps: contacting the fermentation broth of *Bacillus thermoglucosinolates* or its supernatant with a sample containing AFB1 and / or ZEA at 55-65°C for 72 hours; the supernatant is prepared by the following method: centrifuging the fermentation broth of *Bacillus thermoglucosinolates* at 4°C and 8000 r / min for 6 min, collecting the supernatant, filtering it through a 0.22 μm sterile filter membrane, and collecting the supernatant to obtain the antidote.
7. The application according to claim 5, characterized in that: The sample containing AFB1 and / or ZEA is feed or grain; the volume-to-mass ratio of the fermentation broth supernatant to the sample is (1-5):
10.
8. The application according to claim 6, characterized in that: The active ingredient in the antidote is a protein or enzyme. After heat treatment at 100°C for 15 minutes, the degradation rate of AFB1 is still ≥60% and the degradation rate of ZEA is still ≥55%.
9. The application according to claim 6, characterized in that: The antidote, when used at 55-65°C, exhibits a degradation rate of ≥90% for AFB1 at a concentration of 500 μg / L and a degradation rate of ≥85% for ZEA at a concentration of 500 μg / L.
